Goodwin Biotechnology and Aspyrian Therapeutics Collaborate
News Jun 12, 2015
Goodwin Biotechnology, Inc. has partnered with Aspyrian Therapeutics to successfully complete process development, scale‐up, and cGMP manufacturing of their novel Antibody Drug Conjugate (ADC).
Based on achieving this critical milestone, Aspyrian Therapeutics recently submitted and has received FDA’s acceptance of an Investigational New Drug (IND) Application for RM‐1929, their first‐in‐class, precision targeted therapy for cancer, and they will be initiating clinical studies shortly for the treatment of patients with recurrent head and neck cancer.
Aspyrian Therapeutics secured an exclusive license from the National Cancer Institute for the new ADC technology platform, Near‐Infrared Photoimmunotherapy (PIT), which permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor. Because the payload in this unique ADC is inert until it is both in the tumor and activated by a laser using visible light, it overcomes the dose‐limiting adverse effects that have hindered the development of conventional, toxin‐loaded ADC systems.
“The team at Goodwin Biotechnology takes great pride in partnering with our clients and advancing their biopharmaceutical candidates through the development phase and to file INDs,” said SooYoung S. Lee, Ph.D., Chief Operating Officer at Goodwin Biotechnology. “We have worked with numerous clients in the past and it always reinforces our drive and commitment when we’re able to add value to our clients and their product portfolio.”
“I have found that working with the team at Goodwin Biotechnology has been a great pleasure,” noted Miguel Garcia‐Guzman, Ph.D., President and Chief Scientific Officer at Aspyrian Therapeutics. “We were originally impressed by their expertise in Bioconjugation. This perception was reinforced by the flexible and solution‐oriented approach to the complexity of our project. They treated our product as theirs as they orchestrated a flexible and well‐run process. This is our company’s first IND submission and securing the IND was a crucial milestone for our company. It speaks about the quality, timeliness, and process economics that Goodwin Biotechnology puts into every aspect of their work.”
Cancer Comes Back All 'Jacked Up' on Stem CellsNews
Recent work increasingly shows that tumors are not static - the populations of cells that make up a tumor evolve over time in response to treatment, often in ways that lead to treatment immunity. Instead of being defined by a snapshot, tumors are more like a movie. This means that a tumor that recurs after treatment may be much different than the tumor originally seen in a biopsy.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018